Objective: Anticoagulation with unfractionated heparin (UFH) in critically ill cardiac surgery patients has several limitations, including the risk of heparin-induced thrombocytopenia. The use of a direct thrombin inhibitor, such as bivalirudin, might either treat this complication or completely eliminate it. The aim of the present study was to analyze the use of bivalirudin in this setting, as either a secondary drug switching from heparin or as the primary anticoagulant, and to evaluate clinical outcomes.
Design: Propensity-matching retrospective analysis. Setting: A cardiac surgery intensive care unit. Participants: One hundred propensity-matched patients who received heparin or bivalirudin.
Interventions: Bivalirudin was administered as a first-line or second-line drug after heparin discontinuation in case of thrombocytopenia and suspicion of heparin-induced thrombocytopenia. Twenty-six patients (52%) received bivalirudin as a primary anticoagulant, while 24 patients (48%) received bivalirudin after switching from heparin.
Measurements and Main Results: Bivalirudin treatment was associated with a reduction of major bleeding (p ¼ 0.05) compared with the control group. Interestingly, in an intention-to-treat analysis, patients receiving primary bivalirudin showed significant reductions in minor bleeding (p ¼ 0.04), and mortality (p ¼ 0.01) compared with the secondary bivalirudin group and, similarly, compared with the rest of the study population (UFH and secondary bivalirudin patients, p ¼ 0. 01 Conclusions: Novel anticoagulant strategies might play a crucial role in critically ill cardiac surgery patients. In a propensity-matched population, results of the present study showed that primary bivalirudin anticoagulation may reduce bleeding complications and mortality. & 2014 Elsevier Inc. All rights reserved.
KEY WORDS: bivalirudin, heparin, cardiac surgery, mortality, heparin-induced thrombocytopenia P ERIOPERATIVE ANTICOAGULATION after cardiac surgery is performed routinely with unfractionated heparin (UFH). However, UFH-based anticoagulation has several limitations, including a variable anticoagulant response, the inability to effectively inhibit thrombin bound to fibrin, platelet activation, and, more importantly, the risk of heparin-induced thrombocytopenia (HIT). [1] [2] [3] HIT is an immune-mediated disorder characterized by the formation of antibodies against the heparin-platelet factor 4 complex; clinical effects include development of severe thrombocytopenia and, eventually, venous and arterial thrombosis.
Bivalirudin is a direct thrombin inhibitor that acts on both soluble and fibrin-bound thrombin. It has a more predictable anticoagulant effect compared with UFH due to its lack of binding to other plasma proteins. Moreover, it is characterized by an antiplatelet effect due to inhibition of thrombin's plateletactivating properties and the absence of immune-mediated thrombocytopenia. 4 It has been investigated extensively as periprocedural anticoagulation during percutaneous coronary intervention (PCI), with positive effects on mortality, major adverse and cerebrovascular events, and bleeding. [5] [6] [7] [8] [9] [10] [11] Therefore, the rationale for the use of bivalirudin in critically ill cardiac patients is strong.
The aim of the present study was to compare anticoagulation with UFH and bivalirudin in critically ill cardiac surgery patients.
METHODS
Data from 112 critically ill patients who required anticoagulation with UFH or bivalirudin in the cardiac surgical intensive care unit (ICU) of an Italian university hospital between January 2009 and January 2012 were retrospectively analyzed. The study included patients with complicated ICU stay (eg, at least 1 major organ failure requiring supportive or replacement therapy) after scheduled or urgent cardiac surgery or interventional cardiology procedures requiring multiple organ support or extracorporeal membrane oxygenation (ECMO) and ventricular assist device (VAD) implantation.
The initial anticoagulation strategy in the study period was based on UFH. HIT was presumed if the platelet count was less than 100 Â 10 9 /L or decreased more than 50% from the baseline, thus triggering the performance of an immunologic test (ELISA). If the results were questionable, a heparin-induced platelet aggregation assay also was performed. When HIT was presumed, all sources of heparin were removed, and bivalirudin (Angiox, The Medicines Company, Parsippany, NJ) was administered. Afterward, clinical practice shifted to the direct use of bivalirudin as the primary anticoagulant in this setting.
UFH and bivalirudin starting doses were 3 IU/kg/hour and 0.025 mg/kg/hour, respectively, without bolus. In patients with glomerular filtration rate (GFR) o30 mL/min, bivalirudin starting dose was halved. Anticoagulation was monitored by activated partial thromboplastin time (aPTT), repeated every 8 hours, targeted between 45 and 60 seconds. If necessary, drug infusion was increased or decreased by steps never exceeding 15% of the previous dosage. If a supramaximal aPTT value was recorded (that is, an aPTT longer than 80 seconds), drug infusion was discontinued for 2 hours, and then started again at a dose 15% lower.
Additionally, aspirin was administered as clinically appropriate. Warfarin was started only when the platelet count had recovered and if clinically required (patient orally fed, no pericardial or pleural effusions, and mobilized).
Allogeneic blood products were administered according to a specific protocol. Packed red cells (PRC) were transfused to maintain a hemoglobin value of $10 g/dL. Fresh frozen plasma (FFP) was used for the treatment of active bleeding. Platelet concentrates were used in case of active bleeding and platelet count o50 Â 10 9 /L. Data extracted from each patient chart included demographic and clinical characteristics, complete information on the type of procedure performed, previous UFH exposure, HIT test results (immunologic and/or functional assays), UFH/bivalirudin dosing patterns, anticoagulant response, thromboembolic and bleeding complications, and survival.
Patients were divided into 2 groups: Those treated with UFH (group H), and those treated with bivalirudin (group B). Group B included patients who received bivalirudin as a primary anticoagulant (primary bivalirudin, PB), and those who received bivalirudin after switching from UFH (secondary bivalirudin, SB).
Platelets count (PLT), aPTT, international normalized ratio, and antithrombin (AT) activity were recorded immediately before starting the anticoagulation and every 12 hours during treatment. PLT at the end of anticoagulation therapy with UFH/bivalirudin and at discharge from the ICU also were recorded.
Bleeding was divided into major and minor bleeding. Major bleeding included all cases of intracranial, intraocular, retropharyngeal, and retroperitoneal bleeding, persisting hemorrhage requiring either radiologic intervention or surgical revision, a decrease in serum hemoglobin 43 g/dL, and bleeding with the need of transfusion of at least 2 PRC units. Minor bleeding included all cases of overt bleeding not meeting criteria for major bleeding. Thromboembolic complications were defined as DVT, myocardial infarction, embolic cerebrovascular accident, PE, limb ischemia, or any clinically relevant thrombosis.
All data were extracted from clinical record charts. Data are presented as mean Ϯ SD, n (%), or for non-normally distributed variables as median (interquartile range). The Stata 11 software (College Station, TX) was used. Statistical analysis included the twotailed paired t test for normally distributed variables or the KruskalWallis for nonparametric variables. Chi square test or Fisher's exact test was used for the comparison of categoric variables, as appropriate. A two-tailed p value o0.05 was considered significant. Propensity score matching analysis was used to match baseline characteristics between the 2 groups. The following variables were included: Age, gender, body mass index (BMI), chronic renal failure, bleeding diathesis, previous PCI, urgent admission, and ECMO or VAD implantation.
For multivariate analysis, the binary logistic regression model was applied. The initial selection of the variables entered into the model was based on univariate analysis significance. The results of multivariate analysis are presented as the hazard ratio with 95% confidence interval.
The study was approved by the local ethics committee. The need for informed consent was waived for this retrospective analysis of data.
RESULTS
After propensity score matching, 100 patients were analyzed (group B = 50 patients; group H = 50 patients), and 12 patients were excluded. Patients' characteristics and surgical data are reported in Table 1 .
The median duration of anticoagulation was 6 (5-14) days in group B and 6 (4-9) days in group H. Mean baseline PLT at the beginning of treatment was significantly lower in patients Clinical outcomes are shown in Data were further analyzed in the bivalirudin group according to an intention-to-treat analysis (Tables 3 and 4) . Twentyfour patients (48%) in group B received bivalirudin after switching from heparin (SB), while 26 patients (52%) in group A received bivalirudin as a primary anticoagulant (PB).
Minor bleeding was significantly lower in patients receiving primary bivalirudin than in patients receiving bivalirudin after switching from UFH (19.2% v 45.8%; p = 0.04), but no statistically significant reduction in major bleeding in cases of primary bivalirudin therapy (3.8%) versus secondary 
DISCUSSION
This is the first study to compare anticoagulation with UFH and bivalirudin in the postoperative care of critically ill cardiac surgery patients requiring multiple organ support.
Given the high prevalence of thrombocytopenia on one hand and the strong need for anticoagulation on the other, this population is exposed to particularly high risk for both bleeding and thromboembolic complications, thus requiring careful management of anticoagulation and coagulation strategies, 12 which was emphasized by the high mortality reported in the present study. The main finding of this study was that primary anticoagulation with bivalirudin may reduce mortality in this setting.
Both thrombocytopenia and HIT are associated with negative outcomes in cardiac surgery patients, [12] [13] [14] particularly in those on mechanical circulatory support. [15] [16] [17] [18] Nearly all cardiac surgery patients may experience a substantial decrease in the platelet count for several reasons, including platelet activation or dilution during extracorporeal circulation, excessive bleeding without platelet replacement therapy, use of an intra-aortic balloon pump (IABP), and medications such as antibiotics or phosphodiesterase III inhibitors. Furthermore, complications can include circulatory failure or sepsis, with associated multiorgan system dysfunction, which may result in thrombocytopenia and coagulopathy. In case of HIT, early diagnosis and implementation of alternative anticoagulation protocols have a central role, but the "trigger" of HIT evaluation is postoperative thrombocytopenia, which already signals a consumption of platelets, possibly with micro-or macrothromboembolic events. 17 Moreover, results of laboratory tests for HIT usually are not available in real time and are not unequivocal. Finally, HIT-related thrombocytopenia may not superimpose infrequently on prevailing thrombocytopenia secondary to critical illness. 1, 19 In these terms, the use of a nonheparin anticoagulant in the postoperative period could abolish the risk of HIT, its diagnostic dilemmas, and complications. Bivalirudin was first introduced in this clinical practice as an alternative to UFH when the diagnosis of HIT was strongly suspected, according to the American College of Chest Physicians (ACCP) guidelines. 20 Since then, its role has expanded far beyond HIT patients, and it was administered as a primary anticoagulant in thrombocytopenic patients and patients at high risk for thrombocytopenia in this new perspective.
This concept has been well-confirmed by these results, which showed that primary but not secondary bivalirudin reduced the risk of HIT and bleeding and improved survival. Indeed, the trigger for secondary bivalirudin was a thrombocytopenia, confirming its predictive value for an adverse clinical outcome after cardiac surgery.
The use of bivalirudin instead of UFH in critically ill patients also may be appropriate for other needs. UFH binds nonspecifically to plasma proteins and endothelial cells, resulting in a variable anticoagulant response. 21, 22 Its indirect (ATdependent) inhibition of hemostasis may be compromised by the low AT levels commonly found in postcardiac surgery. 23 Moreover, UFH may initiate a negative feedback loop by activating platelets, thus causing the release of UFH neutralizing proteins, such as platelet factor 4 (PF4) and von Willebrand factor. Binding of these proteins to UFH may result in resistance, necessitating administration of higher doses of UFH. 24 Furthermore, UFH may be unable to block fibrinbound thrombin on the surface of extracorporeal supports, thus leading to thrombin-mediated platelet activation and the possibility of thrombus propagation in the extracorporeal device.
25,26
As a further confirmation of the variability of the anticoagulant response to heparin, 19 supramaximal aPTT records were observed in the bivalirudin group versus 2 in the bivalirudin group.
Unlike UFH, bivalirudin does not bind to plasma proteins and endothelial cells and is independent of AT, thus resulting in a more predictable anticoagulant response. 27 It inhibits thrombin that is bound to the fibrin coating the extracorporeal devices surface, 27 potentially allowing for more effective prevention of VAD/ECMO thrombosis and embolic strokes. Moreover, its antiplatelet effect provides a useful adjunct in this specific context, thus questioning the role of further antiplatelet medications. In this respect, it is important to acknowledge that UFH patients in the study had more antiplatelet therapy, and this might have affected bleeding. The authors previously reported that anticoagulation with bivalirudin may represent a superior anticoagulation strategy compared with heparin-based protocols in a case-control study.
28
Several study limitations should be acknowledged. This study was retrospective in design and involves a heterogenous population in whom anticoagulation was dictated by different clinical needs. Moreover, bivalirudin doses administered in the present study were lower than those used in interventional cardiology, as cautious administration is recommended in patients with multi-organ failure and extracorporeal devices. Although specific criteria were used to diagnosis bleeding and thromboembolic complications, the true incidence of thromboembolic events is highly underestimated by clinical evaluation in these types of patients, as shown by a previous study on autopsy findings. 29 In addition, the present study included a treatment bias, as an evolution in practice occurred during the years of the study period, with the use of bivalirudin as primary anticoagulant in both thrombocytopenic patients and patients at high risk for HIT. Furthermore, although results were encouraging in terms of efficacy and did not raise concerns in terms of the safety profile, this was not an efficacy or safety study, and the study design did not include randomization. Finally, as the number of patients in the primary bivalirudin group was small, larger prospective trials are needed to confirm results.
CONCLUSIONS
In conclusion, the present study suggested that anticoagulation for critically ill cardiac surgery patients could be managed effectively by using bivalirudin at low doses, with stable therapeutic effects and fewer adverse events. Moreover, better results could be expected when bivalirudin is administered as a primary anticoagulant. Further randomized controlled studies are needed to confirm these results.
